drugset / Trial / NCT01095276

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

NCT01095276

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators hypothesized that dornase alpha, administered twice a day (BID) by in-line nebulizer, would improve oxygenation, compliance, and time to extubation in adult patients receiving mechanical ventilation.

Timeline

Start
2005-11
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator dornase alfa Protein / enzyme biologic 2.5 mg Other

Indications